Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors...
11 KB (951 words) - 07:29, 1 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
121 KB (13,799 words) - 06:42, 1 July 2024
to be a human polyclonal antibody (-pab) acting on the immune system. Olaratumab is an antineoplastic. Its name is composed of the components olara-t-u-mab...
34 KB (2,906 words) - 19:36, 1 November 2023
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
150 KB (15,741 words) - 10:52, 27 June 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
68 KB (5,993 words) - 00:47, 13 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
92 KB (8,667 words) - 19:29, 28 June 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
13 KB (1,177 words) - 18:50, 10 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
31 KB (3,413 words) - 23:30, 21 June 2024
Ogsiveo Ojemda Ojjaara olaflur (INN) olanzapine (INN) olaquindox (INN) olaratumab (USAN) oleandomycin (INN) Oleptro (Angelini-Labopharm) oletimol (INN)...
7 KB (364 words) - 02:36, 1 July 2024
soravtansine Mogamulizumab Moxetumomab pasudotox Naxitamab Necitumumab Nivolumab Olaratumab Oportuzumab monatox Pembrolizumab Polatuzumab vedotin Prolgolimab Ramucirumab...
12 KB (760 words) - 05:52, 10 June 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
14 KB (1,671 words) - 12:47, 23 April 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
25 KB (2,085 words) - 03:15, 6 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
42 KB (3,935 words) - 04:01, 30 April 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
17 KB (1,489 words) - 05:47, 7 April 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
26 KB (2,542 words) - 19:54, 20 March 2024
patients with GIST tumors bearing the D842V mutation is under recruitment. Olaratumab (LY3012207) is a human IgG1 monoclonal antibody designed to bind to human...
29 KB (3,354 words) - 17:01, 9 December 2023
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
5 KB (412 words) - 23:17, 19 June 2023
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
74 KB (6,565 words) - 05:35, 13 June 2024
Kesimpta mab human CD20 Y chronic lymphocytic leukemia, multiple sclerosis Olaratumab Lartruvo mab human PDGFRA Y cancer Oleclumab mab human 5'-nucleotidase...
135 KB (4,054 words) - 22:35, 2 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
36 KB (4,822 words) - 06:03, 26 June 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
20 KB (1,543 words) - 06:38, 10 March 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
24 KB (1,700 words) - 04:21, 2 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
43 KB (4,740 words) - 14:23, 7 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
34 KB (3,021 words) - 04:42, 11 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
110 KB (10,711 words) - 05:46, 12 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
60 KB (6,879 words) - 09:57, 15 January 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
9 KB (1,081 words) - 04:46, 16 June 2022
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
22 KB (1,787 words) - 05:10, 1 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
23 KB (2,756 words) - 04:47, 10 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
108 KB (12,653 words) - 16:16, 10 July 2024